Waiting On The Eleventh Circuit

While the U.S. Court of Appeals for the Eleventh Circuit continues to consider whether the new statute of limitations in the Sarbanes-Oxley Act of 2002 revives time-barred claims, the district court split on the issue remains unresolved. Two recent decisions from the S.D.N.Y., in prominent cases, come to different conclusions.

In In re Worldcom, Inc. Sec. Litig., 2004 WL 1435356 (S.D.N.Y. June 28, 2004), Judge Cote found that “there is no explicit language in the statute” that would operate to revive time-barred claims and lengthening the statute of limitations in this manner “would affect the substantive rights of the defendants by depriving them of a defense on which they were entitled to rely.” Accordingly, the court held that “Sarbanes-Oxley does not revive previously time-barred private securities fraud claims” and dismissed certain claims in the case that had expired in June 2002 (a month before Sarbanes-Oxley was passed).

In In re AOL Time Warner, Inc. Sec. and “ERISA” Litig., 2004 WL 992991 (S.D.N.Y. May 5, 2004), Judge Kram went in another direction. In that case, the first class action was filed on July 18, 2002 (two weeks before Sarbanes-Oxley was passed). The court held that the plaintiffs’ otherwise time-barred claims would have been revived if the plaintiffs had filed after the passage of Sarbanes-Oxley. Although “in most cases, class actions or otherwise, the date of the first filing is the operative one for statute of limitations purposes,” the court decided that the filing date of the consolidated complaint, September 16, 2002, should be the operative date in the instant case. As a result, the longer statute of limitations in Sarbanes-Oxley applied and the otherwise time-barred claims could proceed. The court justified this rather extraordinary decision by arguing that any other result would punish the plaintiffs for filing too early and lead to a mass opt-out from the class.

Leave a comment

Filed under Motion To Dismiss Monitor

How Deep Is The Safe Harbor?

The PSLRA created a safe harbor for forward-looking statements to encourage companies to provide investors with information about future plans and prospects. Under the first prong of the safe harbor, a defendant is not liable with respect to any forward-looking statement if it is identified as forward-looking and is accompanied by “meaningful cautionary statements” that alert investors to the factors that could cause actual results to differ.

In the case of oral forward-looking statements, the PSLRA specifically provides that the meaningful cautionary statements can be incorporated by reference in a readily available written document. The statute is silent, however, about whether this is also true for written forward-looking statements. Surprisingly, only a few courts have addressed this issue.

In In re Blockbuster Inc., Sec. Litig., 2004 WL 884308 (N.D. Tex. April 24, 2004), the court noted that the PSLRA’s safe harbor is based on the judicially-created bespeaks caution doctrine, which provides that statements must be analyzed in context. The court therefore concluded that “as long as the reference is clear and explicit so that the referenced cautionary language can fairly be viewed as part of the ‘context’ surrounding the written forward-looking statement, the PSLRA safe harbor for written forward-looking statements can be satisfied by meaningful cautionary language that is incorporated by reference.” The court found that its holding was supported by the “illogic” of allowing incorporation by reference for oral statements, where the location of the cautionary statements is likely to be misheard or forgotten, but not allowing it for easily followed written statements.

Holding: Motion to dismiss granted.

Leave a comment

Filed under Motion To Dismiss Monitor

Harvard Law School Settles Estate Claim

Last year, The 10b-5 Daily posted about the unusual legal battle over the estate of Harvey Greenfield. Greenfield was a well-known plaintiffs’ securities class action lawyer who passed away in 2002. Although Greenfield had told people that he planned to leave the bulk of his estate (valued at $35 million) to Harvard Law School, a will could not be located after his death. Harvard filed a claim against the estate. The New York Law Journal reports today that a settlement has been reached between Harvard and Greenfield’s sole living heir to fund a securities law professorship in Greenfield’s name with about $2.8 million.

Leave a comment

Filed under All The News That's Fit To Blog, Curiouser and Curiouser

In-And-Out Traders As Lead Plaintiffs

Matria Healthcare has announced the dismissal of the securities class action pending against the company in the N.D. of Ga. The court’s opinion addresses the issue of whether in-and-out traders (i.e., investors who both bought and sold their shares during the class period) can be effective lead plaintiffs.

Only one person filed suit against Matria on a class action basis and he was subsequently named lead plaintiff. The proposed class period extended from October 24, 2000 to June 25, 2002, when the company disclosed problems with its information technology capabilities, but the lead plaintiff had sold all of his Matria shares on February 6, 2002.

In its opinion (Barr v. Matria Healthcare, Inc., 2004 WL 1551566 (N.D. Ga. July 7, 2004)), the court found that it was “undisputed that the Plaintiff sold his stock in response to an adverse market reaction to the Defendants’ January 30, 2002 press release.” The January 30 press release, however, made no mention of Matria’s information technology problems. As a result, the court found that the lead plaintiff could not demonstrate loss causation because the relevant misrepresentations “were not disclosed until well after the Plaintiff had sold his stock at the still artificially inflated price.”

Holding: Motion to dismiss granted with prejudice (also on other grounds).

Leave a comment

Filed under Lead Plaintiff/Lead Counsel, Motion To Dismiss Monitor

Biotech Woes

The Motley Fool website has an interesting, non-lawyer commentary on the large number of securities class actions that have been filed in the biotech industry over the past few years. The author engages in an informal survey of 100 mid-cap ($100 million to $2 billion) biotech companies and finds that 31, or nearly one-third, are currently facing suits. (The 10b-5 Daily has previously posted about the statistics for biotech cases filed in 2003.)

Quote of note: “Drug development is a high-risk business model, where investigational products frequently fail. Approximately 30% of drugs in phase 3 trials will never gain approval, and roughly 20% of drugs filed for approval with the FDA will get turned down. That’s a pretty high failure rate.”

Quote of note II: “This non-legal advice from a non-lawyer is to stick to the facts of the clinical data and avoid giving opinions on how good the drug is. Don’t say something like ‘potential to be best in class’ or ‘revolutionize the treatment of this disease.’ Such careless comments will be a nightmare if the drug hits a snag. You can bet that the lawyers will be looking for them, too.”

Leave a comment

Filed under All The News That's Fit To Blog

Applying The Fraud-On-The-Market Theory To Research Analysts

Whether and how to apply the fraud-on-the-market theory (i.e., reliance by investors on an alleged misrepresentation is presumed if the company’s shares were traded on an efficient market) to research analyst statements is a controversial issue. It was the subject of a recent appeal by Citigroup in the WorldCom litigation, but the appeal was mooted by the settlement of the case just before the scheduled oral argument.

The 10b-5 Daily has argued that the Second Circuit, in its opinion granting Citigroup’s request for interlocutory appeal, appeared favorably disposed to finding that the fraud-on-the-market theory was not generally applicable to research analyst statements. Judge Rakoff of the S.D.N.Y. apparently agrees with this reading of the opinion.

In DeMarco v. Lehman Brothers, 2004 WL 1506242 (S.D.N.Y. July 6, 2004), a case alleging that a Lehman analyst made buy recommendations for RealNetworks, Inc. stock while secretly holding negative views of the stock, the court has denied the motion for class certification. The court noted that there is a “qualitative difference” between a statement of fact from an issuer and a statement of opinion by a research analyst. In particular, a “well-developed efficient market can reasonably be presumed to translate the former into an effect on price, whereas no such presumption attaches to the latter.” As a result, the court held that the fraud-on-the-market doctrine can apply to a case based on research analyst statements “only where the plaintiff can make a prima facie showing that the analyst’s statements materially impacted the market price in a reasonably quantifiable respect.”

The plaintiffs relied on Lehman Brothers’ promotional materials touting its analyst’s abilities and influence and an expert report (largely based on general studies of the effect of analyst recommendations on stock prices) in arguing that the analyst’s statements inflated the market price for RealNetworks’ stock. The court found that this evidence was insufficient to “warrant invocation of the fraud-on-the-market presumption.”

Holding: Motion for class certification denied.

Quote of note: “[A] statement of opinion emanating from a research analyst is far more subjective and far less certain, and often appears in tandem with conflicting opinions from other analysts as well as new statements from the issuer. As a result, no automatic impact on the price of a security can be presumed and instead must be proven and measured before the statement can be said to have ‘defrauded the market’ in any material way that is not simply speculative.”

The New York Law Journal has an article (via law.com – free regist. req’d) on the decision. Thanks to Adam Savett for sending in a copy of Judge Rakoff’s opinion.

Leave a comment

Filed under Motion To Dismiss Monitor

Mutual Fund Cases In Settlement Talks

The parties in the mutual fund trading practices cases, which have been consolidated in the D. of Md., are in settlement negotiations. The Wall Street Journal has an interesting article (subscrip. required) exploring the ramifications of the mutual funds’ agreement to pay $2.5 billion to settle with the SEC and state regulators. Almost all of these funds will go to mutual fund investors (in part because of the Sarbanes-Oxley provisions allowing the SEC to distribute penalties it obtains to injured investors), which is likely to reduce any settlement in the private lawsuits. (The 10b-5 Daily has posted about the cases frequently, most recently about the lead plaintiff contest.)

Quote of note: “Attorneys for the mutual-fund companies have cited the settlement agreements in their defense, which by some measures total more than the alleged damages. The ‘plaintiffs are tilling a plowed field,’ lawyers for Janus wrote in a court filing.”

Quote of note II: “The plaintiffs’ attorneys are likely to contend in amended complaints due later this month that the fund companies need to prove that they are fully compensating investors for the harm done by the trading. Some of the lawsuits are seeking the return of fund-management fees on the theory that the managers violated their fiduciary duty to investors, an issue not directly addressed by the SEC settlements.”

Leave a comment

Filed under All The News That's Fit To Blog

The Big Breakup In Review

The New York Times had a long feature article in its Sunday edition on the breakup of Milberg Weiss Bershad Hynes & Lerach, widely recognized as the leading plaintiffs’ securities class action firm. The article discusses a number of topics, including the history of Milberg Weiss, the PSLRA, and the recent corporate scandals.

Leave a comment

Filed under All The News That's Fit To Blog

More On Dura

The Financial Times has an article on the U.S. Supreme Court’s decision to grant cert in the Dura Pharmaceuticals case and address the issue of loss causation. The article also discusses the potential impact on the research analyst cases.

Quote of note: “The Supreme Court is not expected to rule on the Dura case until 2005; an appeal in the Merrill Lynch case is due to begin in New York next month, although some lawyers believe that ruling may be put off until after the Supreme Court acts.”

Disclosure: The author of The 10b-5 Daily is quoted in the article.

Leave a comment

Filed under All The News That's Fit To Blog

D&O Insurance Rates Falling

Last year, there was a great deal of concern over the rising costs of directors and officers (“D&O”) insurance. According to an article in the Silicon Valley/San Jose Business Journal (via MSNBC), however, the pendulum has swung the other way. Rates began declining in April of this year and “now many companies are saving between 18 percent and 50 percent.” The article attributes most of the decline to rate competition caused by new underwriters entering the market. (Thanks to the Securities Law Beacon for the link.)

Quote of note: “Those getting the biggest break are stable, middle-market public companies, between $500 million and $1 billion in market cap. This group was hit as hard as anyone when D&O rates started increasing in 2001. Until rates started easing earlier this year, some companies saw increases as high as 300 percent.”

Leave a comment

Filed under All The News That's Fit To Blog